Moderna, Inc.
MRNA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 0.21 | 0.21 | 0.00 |
| FCF Yield | -8.64% | -8.61% | -10.64% | 1.89% |
| EV / EBITDA | -37.03 | -13.38 | -10.89 | -13.26 |
| Quality | ||||
| ROIC | -2.66% | -8.69% | -9.49% | -9.84% |
| Gross Margin | 79.63% | 16.20% | 15.89% | 22.70% |
| Cash Conversion Ratio | 4.24 | 1.11 | 1.07 | -0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -37.65% | -33.81% | -40.33% | -44.66% |
| Free Cash Flow Growth | 5.64% | 20.79% | -484.16% | 117.65% |
| Safety | ||||
| Net Debt / EBITDA | 1.72 | 0.71 | 0.95 | 1.06 |
| Interest Coverage | 0.00 | -907.00 | -1,050.00 | -207.67 |
| Efficiency | ||||
| Inventory Turnover | 0.62 | 0.50 | 0.70 | 6.32 |
| Cash Conversion Cycle | 120.92 | 338.81 | 159.38 | 20.66 |